Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Operating Margin
Arovella Therapeutics Ltd

-5 610.3%
Current
-5 602%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 610.3%
=
Operating Profit
-8.7m
/
Revenue
155.7k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD
-5 610%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
744.2B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
373.9B USD
28%
US
Merck & Co Inc
NYSE:MRK
258.4B USD
34%
CH
Roche Holding AG
SIX:ROG
200.6B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
180.7B CHF
31%
US
Pfizer Inc
NYSE:PFE
146.9B USD
22%
Country AU
Market Cap 189.1m AUD
Operating Margin
-5 610%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 744.2B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.9B USD
Operating Margin
28%
Country US
Market Cap 258.4B USD
Operating Margin
34%
Country CH
Market Cap 200.6B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 180.7B CHF
Operating Margin
31%
Country US
Market Cap 146.9B USD
Operating Margin
22%
No Stocks Found

Arovella Therapeutics Ltd
Glance View

Market Cap
189.1m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.01 AUD
Overvaluation 96%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 610.3%
=
Operating Profit
-8.7m
/
Revenue
155.7k
What is the Operating Margin of Arovella Therapeutics Ltd?

Based on Arovella Therapeutics Ltd's most recent financial statements, the company has Operating Margin of -5 610.3%.